Importance of early treatment in metastatic prostate cancer: a question of life or death
Mené dans 34 pays sur 1 199 patients atteints d'un cancer de la prostate de stade métastatique récemment diagnostiqué, sensible à la castration et à haut risque de récidive, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout d'acétate d'abiratérone et de prednisone à une thérapie anti-androgénique
Patients diagnosed with metastatic prostate cancer have become less common with the widespread use of prostate-specific antigen tests and improved awareness of prostate cancer. Although screening remains controversial, patients who walk into our clinics with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) remain the most challenging to treat group of patients with prostate cancer. These patients generally have a poor prognosis and overall survival times are still only around 3 years, despite substantial improvements during the past 15 years. Why these patients do so poorly compared with those who progress from a localised state to a metastatic state is unclear, but it is probably related to a different underlying biology or simply that the large tumour burden that developed over time has allowed intrinsically resistant clones to form.
The Lancet Oncology , commentaire, 2018